Rahman Group https://validator.w3.org/feed/docs/rss2.html News Home P2Y1 Receptor Antagonists as Anti-Inflammatory Agents Designing Permeation Rules for Gram-Negative Bacteria New Therapeutic Strategies Against Tuberculosis Publications Heme Oxygenase-1 (HO-1) Inhibitors for Cancer Immunotherapy Targeted Protein Degraders (PROTACs) as Anticancer Therapeutics Projects Innovative Payloads for Antibody–Drug Conjugates (ADCs) Novel Antifungal Agents for Multidrug-Resistant Fungal Pathogens Next-Generation Antibiotics for Drug-Resistant Priority Bacteria Chemical Biology Tools to Probe Antimicrobial Resistance Dr Mohammad Askarzadeh About us King’s biotech spinout Pheon Therapeutics Raises $120m to develop novel anticancer agents Grant supports effective antibiotics for people with cystic fibrosis Global action urgently needed to tackle antimicrobial resistance, experts warn Antifungal discovery offers hope against deadly drug-resistant infections New cancer drug boosts effectiveness of chemotherapy – even in resistant tumours King’s biotech spinout re-launches with new name and $68 million funding Team Contact New Generation Modified Azole Antifungals Small-molecule HO-1 inhibitor (KCL-HO-1i) Portfolio Tasnim Ferdous Afroza Rahman Kubra Ekinci Yifei Mo Adela Popi Yuchen Lu Pria Pretheshan Sihan Liu Yunxiao Li Dr Paolo Andriollo Md Ashiqul Islam Emre Demirel Dr Nasima Chowdhury Dr Manasa Punaha Ravindra Professor Khondaker Miraz Rahman